Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01716195 · ClinicalTrials.gov registry record · Phase 2
Induction Chemotherapy Followed by Chemoradiotherapy for Head and Neck Cancer
A Phase 2 study, sponsored by University of California, Davis.
- Completed
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
NCT01716195: Completed Phase 2 study, sponsored by University of California, Davis.
NCT01716195 is a Phase 2 study that has completed, run by University of California, Davis. The registered enrollment target is 18 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (86% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01716195, a Phase 2 study, has completed, sponsored by University of California, Davis.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether human papillomavirus (HPV)-positive head and neck cancer can be treated with a less aggressive regimen of radiation therapy and chemotherapy (paclitaxel) after initially receiving two cycles of chemotherapy (carboplatin/paclitaxel).
Primary Outcome
Defined from date of registration to date of first documentation of progression and/or distant metastasis, or death due to any cause. The true 2-year progression-free survival rate will be estimated by the proportion of efficacy-evaluable patients on study without documentation of disease progression or death 2 years from registration. A 95% confidence interval (CI) for the true progression-free survival rate will be constructed using the Duffy-Santner approach. However, Kaplan-Meier methodology
Interventions
- RADIATION Induction Chemotherapy followed by Response Adapted Chemoradiation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2012-10 |
| Est. Completion | 2020-10-01 |
| Phase | Phase 2 |
What the finished NCT01716195 record still lists
NCT01716195 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (86% lower).
The record links to 0 conditions, and to 1 intervention - of which Induction Chemotherapy followed by Response Adapted Chemoradiation is the first listed.
NCT01716195 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01716195 about?
NCT01716195 is a clinical study titled "Induction Chemotherapy Followed by Chemoradiotherapy for Head and Neck Cancer". The purpose of this study is to determine whether human papillomavirus (HPV)-positive head and neck cancer can be treated with a less aggressive regimen of radiation therapy and chemotherapy (paclitaxel) after initially receiving two cycles of chemotherapy (carboplatin/paclitaxel).
What is the current status of trial NCT01716195?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2012-10. Estimated completion is 2020-10-01.
What interventions are being tested in trial NCT01716195?
The interventions under investigation include: Induction Chemotherapy followed by Response Adapted Chemoradiation (RADIATION).
Who is sponsoring clinical trial NCT01716195?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01716195's enrollment target sits among peer trials
18 1898th of 2000 higher than 98 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia